JPRN-UMIN000024116已完成未知
A retrospective analysis of regorafenib and TAS-102 for advanced or recurrent colorectal cancer - RETAS study
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 46years-old 至 81years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The case that an image evaluation was never accomplished
研究者
相似试验
已完成
1 期
Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard TherapyPretreated Metastatic Colorectal CancerNCT03305913AIO-Studien-gGmbH12
进行中（未招募）
1 期
A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer.Patient with metastatic colorectal cancerMedDRA version: 19.0Level: LLTClassification code 10010028Term: Colorectal cancer Duke's DSystem Organ Class: 100000004864EUCTR2016-002222-37-DKHerlev og Gentofte Hospital60
已完成
不适用
Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational studycolorectal cancerJPRN-UMIN000020416Japanese Society for Cancer of the Colon and Rectum600
招募中
2 期
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRCMetastatic Colorectal CancerNCT05970705Fudan University101
进行中（未招募）
1 期
Regorafenib followed by Nivolumab in patients with Hepatocellular Carcinoma progressing under sorafenibMedDRA version: 20.0 Level: PT Classification code 10073071 Term: Hepatocellular carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hepatocellular carcinomaEUCTR2019-003108-10-ESFundació Clinic per a la Recerca Biomèdica60